Qiagen NV 2024 AR2
The report highlights QIAGEN N.V.'s financial and sustainability performance for the fiscal year 2024. The company achieved net sales of $1.98 billion, driven by its core product portfolio and key growth pillars like QIAstat-Dx and QuantiFERON. On the sustainability front, QIAGEN reduced its absolute Scope 1 and 2 greenhouse gas emissions by 14% compared to 2023 and achieved a plastic footprint reduction of over 25 tons. Additionally, the company mapped its supplier base to support its Science Based Targets initiative commitments and maintained a strong focus on diversity, with women representing 40% of the Supervisory Board.
Company: Qiagen NV
Sector: Health Care
Country: Netherlands
Year: 2024
Type: AR2
Pages: 397
Qiagen NV
Ifrs Annual Report
The report highlights QIAGEN N.V.'s financial and sustainability performance for the fiscal year 2024. The company achieved net sales of $1.98 billion, driven by its core product portfolio and key growth pillars like QIAstat-Dx and QuantiFERON. On the sustainability front, QIAGEN reduced its absolute Scope 1 and 2 greenhouse gas emissions by 14% compared to 2023 and achieved a plastic footprint reduction of over 25 tons. Additionally, the company mapped its supplier base to support its Science Based Targets initiative commitments and maintained a strong focus on diversity, with women representing 40% of the Supervisory Board.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 28, 2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees